Definium Therapeutics (NASDAQ:DFTX) and Tetra Bio-Pharma (OTCMKTS:TBPMF) Head-To-Head Review

Tetra Bio-Pharma (OTCMKTS:TBPMF) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Tetra Bio-Pharma and Definium Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tetra Bio-Pharma	0	0	0	0	0.00
Definium Therapeutics	1	0	8	3	3.08

Definium Therapeutics has a consensus target price of $35.22, suggesting a potential upside of 108.66%. Given Definium Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Tetra Bio-Pharma.

Institutional and Insider Ownership

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Tetra Bio-Pharma and Definium Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tetra Bio-Pharma	N/A	N/A	N/A	N/A	N/A
Definium Therapeutics	N/A	N/A	-$108.68 million	($2.04)	-8.27

Profitability

This table compares Tetra Bio-Pharma and Definium Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tetra Bio-Pharma	N/A	N/A	N/A
Definium Therapeutics	N/A	-86.18%	-62.29%

Summary

Definium Therapeutics beats Tetra Bio-Pharma on 6 of the 8 factors compared between the two stocks.

About Tetra Bio-Pharma

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.